BioWorld

Aug. 29, 2005

View Archived Issues

DOV Halts Ocinaplon Phase III To Check Liver Enzyme Status

Because of potential liver toxicity risks, DOV Pharmaceutical Inc. shut down a Phase III trial of its investigational anti-anxiety agent ocinaplon, a setback that could cause the company to drop the drug altogether. (BioWorld Today) Read More

Inyx Paying UCB $37.5M To Acquire UK Subsidiary

Read More

Able Laboratories: The Rise And Fall Of A Generic Firm

Read More

Renovis' Sciatica Therapy Fizzles In Phase II Studies

Read More

Other News To Note

Read More